139 related articles for article (PubMed ID: 38142835)
1. Tofacitinib is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis.
Wang M; Reynolds KL; Montazeri K; Schaefer EA; Sullivan RJ; Dougan M
Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1539-1541.e2. PubMed ID: 38142835
[TBL] [Abstract][Full Text] [Related]
2. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Bishu S; Melia J; Sharfman W; Lao CD; Fecher LA; Higgins PDR
Gastroenterology; 2021 Feb; 160(3):932-934.e3. PubMed ID: 33096100
[No Abstract] [Full Text] [Related]
4. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib treatment for refractory autoimmune encephalitis.
Jang Y; Lee WJ; Lee HS; Chu K; Lee SK; Lee ST
Epilepsia; 2021 Apr; 62(4):e53-e59. PubMed ID: 33656171
[TBL] [Abstract][Full Text] [Related]
6. Two cases of rheumatoid arthritis complicated by organising pneumonia successfully treated with tofacitinib therapy.
Kodera T; Tsutsumi T; Oka Y; Takeda T; Shirota Y; Kameoka J
Mod Rheumatol Case Rep; 2021 Jul; 5(2):218-225. PubMed ID: 33784938
[TBL] [Abstract][Full Text] [Related]
7. First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis.
Murray K; Floudas A; Murray C; Fabre A; Crown J; Fearon U; Veale D
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33541985
[TBL] [Abstract][Full Text] [Related]
8. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
Yu Z; Wang L; Quan M; Zhang T; Song H
Rheumatology (Oxford); 2021 Apr; 60(4):1700-1707. PubMed ID: 33024992
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients.
Li M; Wong D; Sack JS; Vogel AS; Hodi FS; Fong L; Lai JC; Zucker SD; Grover S
Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1444-1452.e4. PubMed ID: 38401693
[TBL] [Abstract][Full Text] [Related]
10. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Liu LY; Strassner JP; Refat MA; Harris JE; King BA
J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
[TBL] [Abstract][Full Text] [Related]
11. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
12. Interferon-Gamma-Producing CD8
Sasson SC; Slevin SM; Cheung VTF; Nassiri I; Olsson-Brown A; Fryer E; Ferreira RC; Trzupek D; Gupta T; Al-Hillawi L; Issaias ML; Easton A; Campo L; FitzPatrick MEB; Adams J; Chitnis M; Protheroe A; Tuthill M; Coupe N; Simmons A; Payne M; Middleton MR; Travis SPL; ; Fairfax BP; Klenerman P; Brain O
Gastroenterology; 2021 Oct; 161(4):1229-1244.e9. PubMed ID: 34147519
[TBL] [Abstract][Full Text] [Related]
13. The off-label uses profile of tofacitinib in systemic rheumatic diseases.
Zhao Z; Ye C; Dong L
Int Immunopharmacol; 2020 Jun; 83():106480. PubMed ID: 32283509
[TBL] [Abstract][Full Text] [Related]
14. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment of adult Still's disease with tofacitinib in a HIV-2 positive female patient].
Hoff P; Walther M; Wesselmann H; Weinerth J; Feist E; Ohrndorf S
Z Rheumatol; 2020 Dec; 79(10):1046-1049. PubMed ID: 32816071
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib.
Chen YL; Liu LX; Huang Q; Li XY; Hong XP; Liu DZ
Front Immunol; 2021; 12():654376. PubMed ID: 33936080
[TBL] [Abstract][Full Text] [Related]
17. Outcomes after retreatment with MAPK inhibitors and immune checkpoint inhibitors in melanoma patients.
Persa OD; Mauch C
Future Oncol; 2021 Oct; 17(29):3809-3817. PubMed ID: 34254534
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
19. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
